---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-040762"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:39:28.836550+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Evofem Q3 revenue $5.1M (-20% YoY); op loss narrows 81%; debt restructured; generic threat removed

## Summary
- Net product sales $5.1M in Q3 vs $6.4M YoY; selling and marketing expenses cut 75%.
- Net income $66M ($15.34 basic) from debt extinguishment gain; operating loss improved to $3.6M from $18.7M.
- Fourth Amendment to $25M notes: waived default, removed revenue covenant; repurchase possible for as low as $14M.
- Generic drug maker withdrew ANDA; will not seek FDA approval until Evofem Phexxi patents expire (2033).

## SEC filing metadata
- accession: 0001493152-23-040762
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315223040762/0001493152-23-040762-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315223040762/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-040762
- JSON: https://secwatch.observer/filing/0001493152-23-040762.json
- Plain text: https://secwatch.observer/filing/0001493152-23-040762.txt

## Key facts
- Earnings Releases
  Evofem Biosciences, Inc. reported third quarter ended September 30, 2023 results: revenue $5.1 million in net product sales, net income net income was $66.0 million, EPS $15.34 per basic and $0.10 per diluted share.
  - Period: third quarter ended September 30, 2023
  - Revenue: $5.1 million in net product sales
  - Net income: net income was $66.0 million
  - EPS: $15.34 per basic and $0.10 per diluted share
  - Result: reported results
  source text: November 14, 2023 —Evofem Biosciences, Inc. (OTCQB: EVFM) today announced financial results for the third quarter and nine months ended September 30, 2023. Highlights include: ● $5.1 million in net product sales of Phexxi ® (lactic acid, citric acid and potassium bitartrate) for the third quarter of 2023 and $13.4 million year-to-date 2023. ○ More than 82% of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1618835/000149315223040762/0001493152-23-040762-index.htm
- Earnings Releases
  Evofem Biosciences, Inc. reported financial results for three and nine months ended September 30, 2023.
  - Period: three and nine months ended September 30, 2023
  - Result: reported results
  source text: On November 14, 2023, Evofem Biosciences, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1618835/000149315223040762/0001493152-23-040762-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.